Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Opioid-Induced Constipation (OIC) - Overview
Opioid-Induced Constipation (OIC) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Opioid-Induced Constipation (OIC) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Opioid-Induced Constipation (OIC) - Companies Involved in Therapeutics Development
MallInckrodt Plc
Shionogi & Co Ltd
Synergy Pharmaceuticals Inc
Opioid-Induced Constipation (OIC) - Drug Profiles
dolcatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lubiprostone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ldemedine tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
loxone hydrochloride PR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Opioid-Induced Constipation (OIC) - Dormant Projects
Opioid-Induced Constipation (OIC) - Discontinued Products
Opioid-Induced Constipation (OIC) - Product Development Milestones
Featured News & Press Releases
Dec 18, 2018: Shionogi receives positive opinion for Rizmoic in latest announcement from the Committee for Medicil Products for Human Use (CHMP)
Dec 13, 2018: Rizmoic (ldemedine) received a positive opinion for the treatment of opioid-induced constipation
Sep 04, 2018: Shionogi announces upcoming presentations from Symproic (ldemedine) studies at PAINWeek 2018 Annual Conference
Jul 09, 2018: Shionogi Regains Full Rights to Symproic (ldemedine) in the US
Mar 06, 2018: Fifty-Two Week Safety Study on Symproic (ldemedine) for Opioid-induced Constipation (OIC) in Adults with Chronic Non-cancer Pain Published in PAIN
Oct 12, 2017: Shionogi and Purdue Pharma Announce U.S. Availability of Symproic (ldemedine) for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain
Sep 06, 2017: Shionogi and Purdue Pharma to Present Data from ldemedine Studies at PAINWeek 2017 Annual Conference
Jun 07, 2017: Opioid-Induced Constipation therapeutic agent ?Symproic (ldemedine) Tablets 0.2mg’ launched in Japan
Mar 30, 2017: Symproic (ldemedine) Approved for the Treatment of Opioid-Induced Constipation in Japan
Mar 24, 2017: EMA Accepts MAA Submission of Shionogi’s ldemedine for the Treatment of Opioid-Induced Constipation
Mar 23, 2017: FDA Approves Symproic (ldemedine) Once-Daily Tablets C-II for the Treatment of Opioid-Induced Constipation in Adults with Chronic Non-Cancer Pain
Dec 19, 2016: Shionogi and Purdue Pharma Establish Alliance for Joint U.S. Commercialization of ldemedine
Sep 07, 2016: ldemedine Phase III Study Demonstrates Long-Term Safety And Efficacy For The Treatment Of Opioid-Induced Constipation
Jun 06, 2016: Shionogi Announces Acceptance Of New Drug Application In The U.S. For ldemedine For The Treatment Of Opioid-Induced Constipation
May 23, 2016: Two ldemedine Phase III Studies Show Consistent Improvement Of Opioid-Induced Constipation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products by Targets, H1 2019
Number of Products by Stage and Targets, H1 2019
Number of Products by Mechanism of Actions, H1 2019
Number of Products by Stage and Mechanism of Actions, H1 2019
Number of Products by Stage and Routes of Administration, H1 2019
Number of Products by Molecule Types, H1 2019
Number of Products by Stage and Molecule Types, H1 2019


List of Tables


Number of Products under Development for Opioid-Induced Constipation (OIC), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Opioid-Induced Constipation (OIC) - Pipeline by MallInckrodt Plc, H1 2019
Opioid-Induced Constipation (OIC) - Pipeline by Shionogi & Co Ltd, H1 2019
Opioid-Induced Constipation (OIC) - Pipeline by Synergy Pharmaceuticals Inc, H1 2019
Opioid-Induced Constipation (OIC) - Dormant Projects, H1 2019
Opioid-Induced Constipation (OIC) - Discontinued Products, H1 2019